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Toxic shock syndrome (TSS) emerged as a
result of changes in industry and personal
behavior but responded to rapid public health
action, including active surveillance (1). This
illness received national attention in 1980 when
unexplained febrile illness associated with
shock, multiorgan dysfunction, and high death
rates was reported in healthy young women from
several states (2,3). This clinical syndrome had
been described sporadically since the 1920s (4).
The dramatic increase in the number of cases in
1979-80 spurred epidemiologic, clinical, and
laboratory studies that resulted in better
understanding of the association between high-
absorbency tampons and TSS (5). These studies
led to recommendations that substantially
decreased the risk for TSS (6,7).
TSS became a nationally notifiable disease in
1980 (8). After the initial epidemic, the number of
reported cases decreased significantly. In 1986,
active surveillance was conducted in many areas
in the United States (total population 34 million)
to confirm that trend (9). The cumulative
incidence (0.5 per 100,000 population) confirmed
the substantial decrease in the incidence of
menstrual TSS observed in the passive surveil-
lance system. Incidence rates decreased from 6 to
12 per 100,000 among women 12 to 49 years of
age (10,11) in 1980 to 1 per 100,000 among
women 15 to 44 years of age in 1986. These data
also demonstrated that passive surveillance
accurately described the demographic character-
istics and case-fatality ratio of TSS cases (12,13).
Ongoing surveillance in the United States
allows us to estimate the current incidence of
TSS and monitor whether new menstrual or
vaginal products affect the risk for disease.
Other products, including high-absorbency
disposable diapers, have raised similar questions
regarding TSS in children. To address these
questions and describe the current epidemiologic
characteristics and recent temporal trends of the
syndrome, we reviewed data from the ongoing
national surveillance for TSS from 1979 through
1996, focusing on three periods: 1979 to 1980 (the
epidemic years), 1981 to 1986 (a period of
increased TSS awareness, culminating in active
surveillance in 1986), and 1987 to 1996.
The Study
The national TSS surveillance system has
been described (8). Cases of TSS are reported to
the Centers for Disease Control and Prevention
(CDC) by state health departments in standard-
ized case reports that include information on
demographic and clinical characteristics, hospi-
talization status, outcome, laboratory data,
products used during menses, and recurrence of
menstruation-associated cases.
We used the surveillance case definition for
TSS revised in 1981, which requires five clinical
criteria: fever, hypotension, rash, desquamation,
and abnormalities in three or more organ
systems (8). A definite case fulfilled all five
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Figure. Toxic shock syndrome cases,* menstrual vs.
nonmenstrual, United States, 1979–1996.
Table. Demographic characteristics, outcome, and proportion of menstrual cases of toxic shock syndrome, United
States, 1979–1996
No. (%)a by years
  1979-80   1981-86   1987-96 Total cases
Characteristic (n = 1,392) (n = 2,835) (n = 1,069) (n = 5,296)
Female 1,365 (98) 2,594  (92) 958 (90) 4,917 (93)
Median age (yrs), (range)      21 (1-70)      22 (1-87)   25 (3d-82)      22 (3d-87)
White race 1,067 (77) 2,564 (90) 967 (90) 4,598 (91)
Menstrual cases 1,264 (91) 2,021 (71) 636 (59) 3,921 (74)
Deaths (Case-fatality ratio [%])      77 (6)      95 (3.5)   36 (3.5)    208 (4)
aCalculations were done by using as denominator the number of persons for whom the information on the specific characteristic
was available.
criteria (unless the patient died before desqua-
mation), and a probable case fulfilled four of the
five criteria. For the purposes of this analysis
and because information on desquamation was
often unavailable because of death or early
discharge, we included all TSS reports meeting
either definition. A similar change regarding
exclusion of desquamation was adopted in a
retrospective study (14).
A TSS case was considered menstrual if
onset of symptoms occurred within 3 days of the
beginning or end of menses; all other cases were
considered nonmenstrual and were classified
into three categories: surgical wounds, postpar-
tum or postabortion, and other. Information on
recurrent episodes of TSS was collected only
from women with menstrual TSS, by asking
them about a similar previous illness during
menstruation. Data were analyzed by using SAS
6.1 (SAS, Cary, NC). The chi-square test was
used to test for statistical significance.
From 1979 to 1996, 5,296 TSS cases were
reported; 1,035 of these were reported from 1987
to 1996 (Figure). Overall, 93% of all TSS cases
reported from 1979 to 1996 were among women.
Although the proportion of menstrual cases
decreased (Table), TSS affected mostly women.
The median age was 22 years (3 days to 87 years);
91% were white. No significant seasonal
variation was noted. For cases in which the
source of the report was known (n = 2,118), 64%
were reported by infection control practitioners
and 28% by physicians.
Menstrual TSS accounted for 74% of TSS
cases during 1979 to 1996 (n = 5,296); this
proportion, however, declined from 91% during
1979 and 1980 to 71% during 1981 to 1986 and
59% during 1987 to 1996. The median age of
patients with menstrual TSS was 21 years, but
41% (n = 1,591) of menstrual TSS cases occurred
in female patients 13 to 19 years of age. No
significant change in the age distribution of
menstrual cases was noted between the three
periods (median age: 21 years, 1979 to 1980; 20
years, 1981 to 1986; 25 years, 1987 to 1996). Most
(98%) patients with menstrual TSS cases for
which the menstrual product was known
(n = 3,457) reported tampon use, a proportion
that did not change; 89% used tampons only,
while 5.0% used both tampons and pads and 3%
used tampons and minipads. The level of tampon
absorbency was reported in only 41% (n = 1,385)
of cases: 28% of patients used regular tampons,
while 71% used super-absorbency tampons.
Staphylococcus aureus was isolated from 90% of
women with menstrual TSS who had vaginal
cultures performed (n = 2,536). Of all the women
with menstrual TSS, 1,606 (30%) responded to
the question regarding recurrent disease, and
10% reported a previous illness similar to their
TSS episode.
 Nonmenstrual cases also occurred mostly in
women (73%) and whites (87%). During 1987 to
1996, the proportion of all TSS cases that were809 809 809 809 809 Vol. 5, No. 6, November–December 1999 Emerging Infectious Diseases
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nonmenstrual averaged 41% (30% to 55%). Of
nonmenstrual cases, 18.3% were reported after
surgical procedures, 11.5% were postpartum or
postabortion, and 23.1% had nonsurgical
cutaneous lesions. The proportion of all
nonmenstrual cases reported after surgical
procedures increased from 14% during 1979 to
1986 to 27% during 1987 to 1996 (p <0.05).
Among female nonmenstrual case-patients, 12%
reported using barrier contraceptives (sponges
and diaphragms); this proportion was, however,
significantly less (p <0.05) in 1987 to 1996 (6%)
than in 1979 to 1986 (14%). Fifty cases of TSS in
children < 5 years of age were reported during
the 17-year period; more than half of these
occurred in children < 2 years of age, and most
(61.7%) were associated with nonsurgical
cutaneous lesions. The percentage of TSS
associated with nonsurgical cutaneous lesions
(23.1%) was higher among younger patients
(overall case-fatality ratio 4% [n = 2 deaths]) than
among patients with other nonmenstrual cases.
Hospitalization status was known for 2,930
patients; 98% were hospitalized. The overall TSS
case-fatality ratio was 4.1% (3% for menstrual
cases, 5% for nonmenstrual cases) and was
significantly higher among nonmenstrual cases
(p <0.005). Among menstrual cases, the case-
fatality ratio decreased significantly with time
(from 5.5% in 1979 and 1980, to 2.8% in 1981 to
1986, to 1.8% in 1987 to 1996, chi-square for
linear trend [p = 0.0001]). This trend was not
observed among nonmenstrual cases (for the
three time periods: 8.5%, 5.3%, and 6%,
respectively).
Conclusions
Our review of recent passive surveillance
data confirms the declining trend previously
noted by active surveillance in 1986. Changes
observed in the epidemiologic characteristics of
TSS include an increase in the proportion of
nonmenstrual cases and the difference in the
risk for death between menstrual and
nonmenstrual cases.
A number of factors could account for the
observed decline, including the decrease in
tampon absorbency, the standardized labeling
required by the U.S. Food and Drug Administra-
tion; greater awareness of TSS among women;
and the proliferation of educational materials for
women, including tampon package inserts (12).
However, at least 40% of menstrual TSS cases
continue to affect women 13 to 19 years old, an
age group not as likely to be aware of the risk
for TSS and for whom further education may
be needed.
Over the last few years, two changes have
occurred in tampon use and composition: 1) All-
cotton tampons have been introduced and
marketed as an alternative product; in vitro
studies have not, however, found any differences
in the effects of these new tampons on the
production of toxic shock syndrome toxin-1
(TSST-1) or its adsorption (15). 2) Tampons
marketed specifically for overnight use have also
been introduced. TSST-1 toxin production is not
the only indicator of the potential risk for TSS.
Previous case-control studies found that exclu-
sive use of tampons was associated with a higher
risk for TSS than use in conjunction with pads
(13). Continued surveillance will monitor the
effect of these changes on TSS occurrence.
However, because the syndrome is rare, only large
changes in the use of higher absorbency products
would be likely to come to public health attention.
 One of the important changes in the
epidemiology of TSS is the increasing proportion
of nonmenstrual cases, in particular, cases
reported after surgical procedures. The factors
contributing to this increase may include
changes in delivery of surgical health-care
services, with an increase in both outpatient
procedures and the use of prosthetic devices.
Hospitalizations caused by infections from
prosthetic devices and postoperative infections
increased significantly from 1980 to 1994 in the
United States (16). In addition, the case-fatality
ratio of nonmenstrual TSS cases did not decline,
although the case-fatality ratio of menstrual TSS
did. This difference in death rates could be due to
several factors: nonmenstrual TSS may occur in
less healthy (e.g., older) persons; diagnostic and
reporting biases may result in more sensitive
detection of severe cases of nonmenstrual TSS;
decreased awareness of nonmenstrual TSS
among health-care professionals may lead to
increased deaths because of late treatment; and
the nonspecific signs and symptoms of postopera-
tive TSS may delay diagnosis (17). Further
studies are needed to validate the difference in
deaths between the two types of TSS and to
clarify the risk factors for nonmenstrual TSS.
Recent molecular studies of the gene that carries
toxic shock toxin (18) may contribute to a better
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transmission of toxin-producing strains of
S. aureus and could improve prevention.
Physicians, in particular surgeons, and other
health-care professionals may need further
education about the risks for nonmenstrual TSS.
Dr. Hajjeh is a medical epidemiologist in the
Division of Bacterial and Mycotic Diseases Branch,
CDC. Her areas of expertise and research interests
include epidemiology of mycotic diseases, bacterial
meningitis, and unexplained critical illnesses of
possible infectious etiology.
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